Clal Biotechnology (Israel) Overlap Studies Bollinger Bands Overview

    CBI -- Israel Stock  

    ILS 318.60  2.60  0.82%

    Clal Biotechnology overlap-studies tool provides you with the Overlap Studies execution environment for running Bollinger Bands study against Clal Biotechnology. Clal Biotechnology overlay technical analysis usually involve calculating upper and lower limits of price movements based on various statistical techniques. Please specify the following input to run this model: Time Period, Deviations up, Deviations down, and MA Type.
    Horizon     30 Days    Login   to change

    Time Period
    Deviations up
    Deviations down
    MA Type
      Portfolio Suggestion  Portfolio Suggestion  
    Execute Study
    We are not able to run technical analysis function on this symbol. We either do not have that equity or its historical data is not available at this time. Please try again later.

    Additional Technical Research

    Current Sentiment - CBI

    Clal Biotechnology Investor Sentiment

    Most of Macroaxis users are currently bullish on Clal Biotechnology Industries Ltd. What is your opinion about investing in Clal Biotechnology Industries Ltd? Are you bullish or bearish?
    98% Bullish
    2% Bearish

    Current Thematic Trending

    Purchased over 10K shares
    Traded a day ago for 0.51
    ATS Automation Tooling Systems
    Purchased over 100 shares
    Traded a day ago for 15.55
    Artificial Intelligence
    Purchased over 20 shares
    Traded a day ago for 145.25
    Macroaxis Index
    Purchased over 20 shares
    Traded a day ago for 135.31
    Macroaxis Index
    Purchased over 20 shares
    Traded a day ago for 135.31
    Driverless Cars
    Purchased over 70 shares
    Traded a day ago for 35.38
    Check also Trending Equities. Please also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.